Effect of CPT-11 in combination with other anticancer agents in lung cancer cells

Xin Hai Pei, Yoichi Nakanishi, Koichi Takayama, Feng Bai, Masayuki Kawasaki, Nobuko Tsuruta, Keiko Mizuno, Nobuyuki Hara

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

To determine the optimal combination of commonly used anticancer agents with 7-ethyl-10-hydroxy-camptothecin (SN-38), an active metabolite of 7-ethyl-10-[4(1-piperidino)1-piperidino] carbonyloxy camptothecin (CPT-11), for chemotherapy of lung cancer, we studied the effects of SN-38 in combination with six representative anticancer agents on the human small cell lung cancer (SCLC) cell line, NCl N417, and the non-small cell lung cancer (NSCLC) cell line, PC-9. The anticancer activity was evaluated by MTT assay and the effects of drug combinations on ID50 were analyzed by an improved isobologram method. In the SCLC cell line, supra-additive effect was observed for SN-38 in combination with cisplatin, etoposide (VP-16) and paclitaxel (Taxol). An additive effect was observed for its combination with bleomycin. Sub-additive and protective effects were found in combination with adriamycin (ADR) and 5-fluorouracil (5-FU). In the NSCLC cell line, supra-additive and marginal supra-additive effects were found for SN-38 in combination with VP-16, ADR, 5-FU and bleomycin. The others showed additive effects with SN-38. No drug showed sub-additive and protective effects with SN-38. These results suggest that all the drugs we selected can be used with SN-38 simultaneously for NSCLC, while for SCLC, cisplatin, VP-16 and Taxol are the most suitable for combination with SN-38.

Original languageEnglish
Pages (from-to)231-237
Number of pages7
JournalAnti-cancer drugs
Volume8
Issue number3
DOIs
Publication statusPublished - Apr 23 1997

Fingerprint

irinotecan
Antineoplastic Agents
Lung Neoplasms
Etoposide
Small Cell Lung Carcinoma
Paclitaxel
Non-Small Cell Lung Carcinoma
Cell Line
Bleomycin
Fluorouracil
Doxorubicin
Cisplatin
Camptothecin

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Cite this

Pei, X. H., Nakanishi, Y., Takayama, K., Bai, F., Kawasaki, M., Tsuruta, N., ... Hara, N. (1997). Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anti-cancer drugs, 8(3), 231-237. https://doi.org/10.1097/00001813-199703000-00003

Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. / Pei, Xin Hai; Nakanishi, Yoichi; Takayama, Koichi; Bai, Feng; Kawasaki, Masayuki; Tsuruta, Nobuko; Mizuno, Keiko; Hara, Nobuyuki.

In: Anti-cancer drugs, Vol. 8, No. 3, 23.04.1997, p. 231-237.

Research output: Contribution to journalArticle

Pei, XH, Nakanishi, Y, Takayama, K, Bai, F, Kawasaki, M, Tsuruta, N, Mizuno, K & Hara, N 1997, 'Effect of CPT-11 in combination with other anticancer agents in lung cancer cells', Anti-cancer drugs, vol. 8, no. 3, pp. 231-237. https://doi.org/10.1097/00001813-199703000-00003
Pei XH, Nakanishi Y, Takayama K, Bai F, Kawasaki M, Tsuruta N et al. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anti-cancer drugs. 1997 Apr 23;8(3):231-237. https://doi.org/10.1097/00001813-199703000-00003
Pei, Xin Hai ; Nakanishi, Yoichi ; Takayama, Koichi ; Bai, Feng ; Kawasaki, Masayuki ; Tsuruta, Nobuko ; Mizuno, Keiko ; Hara, Nobuyuki. / Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. In: Anti-cancer drugs. 1997 ; Vol. 8, No. 3. pp. 231-237.
@article{60e404e4901241eb9fbf2e00152932b4,
title = "Effect of CPT-11 in combination with other anticancer agents in lung cancer cells",
abstract = "To determine the optimal combination of commonly used anticancer agents with 7-ethyl-10-hydroxy-camptothecin (SN-38), an active metabolite of 7-ethyl-10-[4(1-piperidino)1-piperidino] carbonyloxy camptothecin (CPT-11), for chemotherapy of lung cancer, we studied the effects of SN-38 in combination with six representative anticancer agents on the human small cell lung cancer (SCLC) cell line, NCl N417, and the non-small cell lung cancer (NSCLC) cell line, PC-9. The anticancer activity was evaluated by MTT assay and the effects of drug combinations on ID50 were analyzed by an improved isobologram method. In the SCLC cell line, supra-additive effect was observed for SN-38 in combination with cisplatin, etoposide (VP-16) and paclitaxel (Taxol). An additive effect was observed for its combination with bleomycin. Sub-additive and protective effects were found in combination with adriamycin (ADR) and 5-fluorouracil (5-FU). In the NSCLC cell line, supra-additive and marginal supra-additive effects were found for SN-38 in combination with VP-16, ADR, 5-FU and bleomycin. The others showed additive effects with SN-38. No drug showed sub-additive and protective effects with SN-38. These results suggest that all the drugs we selected can be used with SN-38 simultaneously for NSCLC, while for SCLC, cisplatin, VP-16 and Taxol are the most suitable for combination with SN-38.",
author = "Pei, {Xin Hai} and Yoichi Nakanishi and Koichi Takayama and Feng Bai and Masayuki Kawasaki and Nobuko Tsuruta and Keiko Mizuno and Nobuyuki Hara",
year = "1997",
month = "4",
day = "23",
doi = "10.1097/00001813-199703000-00003",
language = "English",
volume = "8",
pages = "231--237",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effect of CPT-11 in combination with other anticancer agents in lung cancer cells

AU - Pei, Xin Hai

AU - Nakanishi, Yoichi

AU - Takayama, Koichi

AU - Bai, Feng

AU - Kawasaki, Masayuki

AU - Tsuruta, Nobuko

AU - Mizuno, Keiko

AU - Hara, Nobuyuki

PY - 1997/4/23

Y1 - 1997/4/23

N2 - To determine the optimal combination of commonly used anticancer agents with 7-ethyl-10-hydroxy-camptothecin (SN-38), an active metabolite of 7-ethyl-10-[4(1-piperidino)1-piperidino] carbonyloxy camptothecin (CPT-11), for chemotherapy of lung cancer, we studied the effects of SN-38 in combination with six representative anticancer agents on the human small cell lung cancer (SCLC) cell line, NCl N417, and the non-small cell lung cancer (NSCLC) cell line, PC-9. The anticancer activity was evaluated by MTT assay and the effects of drug combinations on ID50 were analyzed by an improved isobologram method. In the SCLC cell line, supra-additive effect was observed for SN-38 in combination with cisplatin, etoposide (VP-16) and paclitaxel (Taxol). An additive effect was observed for its combination with bleomycin. Sub-additive and protective effects were found in combination with adriamycin (ADR) and 5-fluorouracil (5-FU). In the NSCLC cell line, supra-additive and marginal supra-additive effects were found for SN-38 in combination with VP-16, ADR, 5-FU and bleomycin. The others showed additive effects with SN-38. No drug showed sub-additive and protective effects with SN-38. These results suggest that all the drugs we selected can be used with SN-38 simultaneously for NSCLC, while for SCLC, cisplatin, VP-16 and Taxol are the most suitable for combination with SN-38.

AB - To determine the optimal combination of commonly used anticancer agents with 7-ethyl-10-hydroxy-camptothecin (SN-38), an active metabolite of 7-ethyl-10-[4(1-piperidino)1-piperidino] carbonyloxy camptothecin (CPT-11), for chemotherapy of lung cancer, we studied the effects of SN-38 in combination with six representative anticancer agents on the human small cell lung cancer (SCLC) cell line, NCl N417, and the non-small cell lung cancer (NSCLC) cell line, PC-9. The anticancer activity was evaluated by MTT assay and the effects of drug combinations on ID50 were analyzed by an improved isobologram method. In the SCLC cell line, supra-additive effect was observed for SN-38 in combination with cisplatin, etoposide (VP-16) and paclitaxel (Taxol). An additive effect was observed for its combination with bleomycin. Sub-additive and protective effects were found in combination with adriamycin (ADR) and 5-fluorouracil (5-FU). In the NSCLC cell line, supra-additive and marginal supra-additive effects were found for SN-38 in combination with VP-16, ADR, 5-FU and bleomycin. The others showed additive effects with SN-38. No drug showed sub-additive and protective effects with SN-38. These results suggest that all the drugs we selected can be used with SN-38 simultaneously for NSCLC, while for SCLC, cisplatin, VP-16 and Taxol are the most suitable for combination with SN-38.

UR - http://www.scopus.com/inward/record.url?scp=0030887027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030887027&partnerID=8YFLogxK

U2 - 10.1097/00001813-199703000-00003

DO - 10.1097/00001813-199703000-00003

M3 - Article

C2 - 9095327

AN - SCOPUS:0030887027

VL - 8

SP - 231

EP - 237

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 3

ER -